Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
Condition: Influenza
MeSH terms: Influenza, Human
Intervention: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine); Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Intervention description: Influenza vaccine; Influenza vaccine
Intervention MeSH terms: Vaccines
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 116.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Influenza; Influenza Vaccine

Summary:

      To submit remaining available sera to Center for Biologics Evaluation and Research (CBER) for
      further analysis by the Food and Drug Administration (FDA), the Center for Disease Control
      and Prevention (CDC) and the World Health Organization (WHO) to support selection and
      recommendation of antigen strains for subsequent influenza vaccines.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participant aged 18 years or older on the day of inclusion.

          -  Participant able to attend scheduled visits and to comply with the study procedures
             during the entire duration of the study.

          -  Participant is in reasonably good health as assessed by the investigator.

          -  Participant willing and able to meet protocol requirements.

          -  Participant willing and able to give informed consent.

          -  For a woman, inability to bear a child or negative serum/urine pregnancy test.

        Exclusion Criteria:

          -  Self-reported allergy to egg proteins, chicken proteins, or one of the constituents of
             the vaccine, such as thimerosal or formaldehyde.

          -  An acute illness with or without fever (temperature ≥ 99.5 °F oral) in the 72 hours
             preceding enrollment in the trial.

          -  Clinically significant findings in vital signs (including temperature ≥ 99.5 °F oral)
             on review of systems.

          -  Self-reported history of severe adverse event to any influenza vaccine.

          -  Laboratory-confirmed influenza infection or vaccination against influenza in the 6
             months preceding enrollment in the study.

          -  Any vaccination in the 14 days preceding enrollment in the study or scheduled between
             Visit 1 and Visit 3.

          -  Vaccination planned in the 4 weeks following Fluzone® vaccination at Visit 1.

          -  Participation in any other interventional drug or vaccine trial within the 30 days
             preceding or during enrollment into this study.

          -  Immunocompromising or immunosuppressive therapy (including systemic steroid use for 2
             weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment,
             planned during the period of this study, or at any time within the past 6 months.

          -  Receipt of blood or blood products within the 3 months preceding enrollment in the
             study.

          -  Diabetes mellitus requiring pharmacological control.

          -  Any condition that in the opinion of the investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine.

          -  Person deprived of freedom by an administrative or court order (having legal or
             medical guardian).

          -  For women of childbearing potential, a positive urine pregnancy test, breast feeding,
             or not using a medically approved form of contraception for the duration of the trial.

          -  Current abuse of alcohol or drug addiction that may interfere with the subject's
             ability to comply with trial procedures.

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.

          -  Prior personal history of Guillain-Barré syndrome.